AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Nocturnal Blood Pressure Reduction with Baxdrostat: A Targeted Literature Review and Meta-Analysis
By Liu J, Xing C, Liu J et al.
Background: Nocturnal blood pressure (BP) is a stronger predictor of cardiovascular events than daytime or clinic BP. Aldosterone excess plays a key role in resistant hypertension and blunted nocturnal BP dipping. Baxdrostat, a highly selective aldosterone synthase inhibitor, has recently completed phase 2/3 clinical trials. This targeted literature review and meta-analysis synthesizes available evidence on the efficacy of baxdrostat for nocturnal BP reduction. Methods: We systematically searched PubMed, ClinicalTrials.gov, and major conference proceedings (2023-2026) for randomized controlled trials evaluating baxdrostat in adults with uncontrolled/resistant hypertension. Studies reporting ambulatory BP monitoring data, specifically nocturnal BP, were included. A random-effects meta-analysis was performed for nocturnal systolic BP reduction. Heterogeneity was assessed using I ² statistics. Results: Three trials met inclusion criteria (BrigHTN phase 2, BaxHTN phase 3, Bax24 phase 3), enrolling 1,262 patients with resistant or uncontrolled hypertension. In the pooled analysis of 1,028 patients with resistant hypertension, baxdrostat 2 mg reduced nocturnal systolic BP by a placebo-adjusted mean of 13.2 mmHg (95% CrI: -15.8 to -10.6; I ² =0%). In the Bax24 trial specifically, the placebo-adjusted reduction in night-time ambulatory systolic BP was 13.9 mmHg (95% CrI: -17.5 to -10.3; p<0.0001). The proportion of patients achieving nocturnal systolic BP dipping (>10%) increased significantly with baxdrostat versus placebo (OR: 2.8, 95% CrI: 1.9-4.2). Hyperkalemia (serum K ⁺ >6.0 mmol/L) occurred in 2.6% of baxdrostat-treated patients versus 0.4% with placebo. Conclusions: Baxdrostat significantly reduces nocturnal BP in patients with resistant hypertension. The magnitude of nocturnal BP reduction is clinically meaningful and may confer cardiovascular protection beyond that predicted by office BP measurements alone. Further trials targeting high-risk nocturnal hypertension phenotypes are warranted.